Resolvin D2 attenuates chronic pain–induced depression-like behavior in mice

• Main Authors: Deyama, S. (Author), Hitora-Imamura, N. (Author), Minami, M. (Author), Suzuki, H. (Author)
• Format: Article
• Language: English
• Published: John Wiley and Sons Inc 2021
• Subjects: animal; animal experiment; animal model; Animals; antidepressant; antidepressant activity; antidepressant agent; Antidepressive Agents; Article; chloral hydrate; chronic pain; Chronic Pain; chronic stress; controlled study; depression; Depression; docosahexaenoic acid; Docosahexaenoic Acids; fatty acid derivative; immobility time; isoflurane; locomotion; male; Mice; mouse; n-3 polyunsaturated fatty acid; neuropathic pain; nonhuman; open field test; pain; pain threshold; paw withdrawal threshold; peroneus nerve; resolvin; resolvin D2; spared nerve injury; tail suspension test; tibial nerve; total distance traveled; unclassified drug; von Frey test
• Online Access: View Fulltext in Publisher

 Aim: We previously demonstrated that intracerebroventricular injection of resolvin D2 (RvD2), a bioactive lipid mediator derived from docosahexaenoic acid, ameliorated depression-like behavior in lipopolysaccharide-induced and chronic mild stress–induced mouse models of depression. In the present study, we examined the antidepressant effect of RvD2 on chronic pain–induced depression-like behavior. Methods: To prepare the neuropathic pain model, mice were subjected to surgery for unilateral spared nerve injury. Two weeks after surgery, the antidepressant effect of RvD2 was examined using the tail suspension test. Results: Chronic pain significantly increased immobility time, and this depression-like behavior was attenuated by intracerebroventricular injection of RvD2 (10 ng). No effect of RvD2 on the locomotor activity was observed. Conclusion: RvD2 produces an antidepressant effect in a murine model of chronic pain–induced depression and may be a promising lead for the development of novel antidepressants. © 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.